
### **Oral Drug Delivery Solutions**

An integrated portfolio of functional excipients, delivery technologies and services to release the true value of your oral solid dosage forms





### Make Evonik Health Care Your Competitive Advantage

Evonik is one of the world's leading specialty chemical companies. In 2021, our more than 33,000 employees produced sales of more than €15 billion and an operating result (EBITDA) of €2.4 billion. We hold market leading positions in 80% of our businesses, and are active across more than 100 countries and 175 sites globally.


Evonik Health Care is a global strategic partner for advanced drug delivery solutions. We combine highly versatile platforms of functional excipients for oral and parenteral dosage forms, with innovative technologies and best-in-class formulation development, manufacturing and regulatory services.

Pharmaceutical companies worldwide leverage our distinctive products and value-adding services to enhance drug effectiveness, reduce project complexity, increase speed to market and strengthen supply security.



By helping to transform your APIs into high-performance medicines, we can become Your Competitive Advantage.

## YOUR GLOBAL PARTNER FOR ADVANCED OR AL DRUG DELIVERY



## RELEASE THE TRUE VALUE OF YOUR ORAL SOLID DOSAGE FORMS



### EUDRAGIT® functional polymers

The versatility and reliability to protect the API, boost drug performance and reduce formulation risk

### EUDRACAP® functional ready-to-fill capsules

The fast and reliable solution to optimize the release profile of your drug, protect active ingredients, and help accelerate speed to market



### **Delivery Technologies**

Differentiated solutions for modified release to enhance drug efficacy and generate superior targeting outcomes



#### Formulation Services

Best-in-class services to reduce project complexity from concept to the final dosage form to increase speed to market



PARTNERSHIP

### Clinical and Commercial Supply

High-quality GMP clinical production, robust scale-up to commercialization through partner with on-site production support and trouble-shooting



### Regulatory Support

Leverage the worldwide monograph status of our excipients and local market expertise for regulatory 'peace of mind'

### 1

## UNRIVALLED VERSATILITY TO UNLOCK THE POTENTIAL OF YOUR API

Our platform of polymers can be used individually or combined to match virtually any target release profile

#### EUDRAGIT® formulations to design individual immediate, delayed or sustained release profiles

- Single or multiple EUDRAGIT® polymer layers
- Combination of EUDRAGIT® polymers
- Combination of EUDRAGIT® polymers and other excipients or substances
- Inert core with combination of EUDRAGIT® polymers and API layer
- Ready-to-use mixtures




#### **EUDRACAP®**

Optimize gastric resistance, boost intestinal absorption and enhance bioavailability with EUDRACAP® functional, ready-to-fill capsules.

- An effective, precisely tailored functional coating
- Easy to open and close on standard equipment
- Reliable protection and precise, rapid release





# THE FLEXIBILITY TO ADDRESS SPECIFIC FUNCTIONALITY REQUIREMENTS



#### THE EUDRAGIT® ADVANTAGE

- · A proven record for safety and performance in marketed oral solid dosage forms spanning more than 70 years
- Ideal for all oral solid dosage forms including tablets, capsules, and multiparticulates
- Easy to handle and compatible with all relevant process technologies
- Consistent quality and global supply security at any clinical or commercial scale
- Unparalleled technical application and formulation expertise across coatings, formulations and finished dosage forms



#### **IMMEDIATE RELEASE**

Protect the Drug. Boost Patient Compliance.

- High-gloss easy to process cosmetic and functional coatings
- Neutral in taste and smell to mask API bitterness or unpleasant odors
- Smooth surfaces as thin as  $10 20 \mu m$  to improve swallowability
- Reliable protection and stability for APIs sensitive to light, moisture and oxygen
- Insoluble in saliva and readily soluble in the stomach for improved absorption
- Custom-made, easy-to-mix powder blends for rapid suspension preparation



#### **DELAYED RELEASE**

Protect the API. Avoid Discomfort. Improve Absorption.

- A broad, easy-to-combine enteric platform to achieve a specific dissolution pH
- Highly effective and stable polymers for precise targeting and rapid dissolution
- Well-defined solutions to protect the gastric mucosa from aggressive actives
- Strong expertise in safeguarding the transit of APIs sensitive to gastric fluid
- Options to improve coating productivity and reduce process and cleaning time
- Ready-to-fill coated capsules for accelerated time to market



#### **SUSTAINED RELEASE**

Optimize Drug Effectiveness. Improve Patient Compliance.

- Sustained, modulated or custom release profiles controlled by diffusion barriers
- Multiple combination options to precisely control passage through the GIT
- Proficient in daily dosage forms including multiparticulates and matrix tablets
- Insoluble with pH-independent swelling and options for high or low permeability
- Options to improve coating productivity and reduce process and cleaning time




#### **SOLUBILITY ENHANCEMENT**

Increase bioavailability. Address poor solubility.

- Suitable carriers for all process technologies such as spray drying, HME and top-spray granulation
- Highly specialized in amorphous solid dispersions (ASDs)
- Development and manufacturing service for particle-engineered free flowing ASDs
- Predictive systems to select the best carrier excipient and process parameters
- Various downstreaming options to improve dosage forms and speed to market



# OPTIMIZE DRUG EFFICACY WITH SUPERIOR TARGETING OUTCOMES



ileocolonic region

tomized for rapid dissolution in the

Phoral® is a proprietary technology from Intract Pharma Ltd.

or below for effective targeting of

the upper small intestine

a pH triggered polymer with a

polysaccharide

# HARNESS THE VALUE OF OUR BEST-IN-CLASS PROJECT SERVICES



#### 1 COMPREHENSIVE SUPPORT

Extensive polymer and formulation support from the first sample to the final dosage form

#### 2 DECADES OF TECHNICAL EXPERTISE

Projects led by scientists and pharmacists with in depth technical and scientific knowledge

#### 3 GLOBAL LABORATORY NETWORK

Access to nine formulation and application labs worldwide including local onsite support

#### 4 PROCESS TECHNOLOGY EXPERTISE

Strong capabilities across all relevant process technologies and equipment

#### 5 SUPPORTING SCALE-UP AND LAUNCH

Broad knowledge of physiological aspects, clinical requirements and GMP scale-up

#### **6** STRONG RECORD OF ACHIEVEMENT

Decades of commercial project success for small molecules or biologics

#### 7 ANY ORAL SOLID DOSAGE FORM

Deep expertise across complex dosage forms

#### 8 LOCAL MARKET EXPERTISE

Highly familiar with local regulatory processes and requirements

#### 9 QUALITY BY DESIGN APPROACH

QbD principles guide each process step to reduce risk and improve speed to market

#### 10 HANDLING OF SPECIAL SUBSTANCES

HPAPI down to  $1 \mu g/m^3$  OEL, biological materials up to biosafety level BSL-2 as well as controlled substances

# CREATING EXCEPTIONAL VALUE FROM FEASIBILITY TO FINAL DOSAGE FORM

PRE-FORMULATION SERVICES	<ul> <li>Fast-track feasibility studies</li> <li>Rapid evaluation of and compatibility with excipients</li> <li>Selection of formulation technologies</li> </ul>	
FORMULATION DEVELOPMENT	<ul> <li>Formulation and reformulation projects</li> <li>Technology matching to target release profile</li> <li>Prototypes for stability or preclinical studies</li> <li>Process development and scale-up</li> </ul>	
ANALYTICAL SERVICES	<ul> <li>Comprehensive range of analytical methods to support development and manufacturing projects</li> <li>Stability program testing</li> <li>Scanning electron microscopy</li> <li>Dissolution testing using USP I (Basket), USP II (Paddle) and USP IV (Flow Through Cell) and biorelevant media</li> </ul>	
PRODUCTION, SCALE-UP AND COMMERCIAL SUPPLY	<ul> <li>Process technology expertise non-GMP and GMP scale (through partnering)</li> <li>On-site production support and troubleshooting</li> <li>CMO review and recommendation for clinical and commercial scale-up</li> <li>Transfer to production site</li> </ul>	

### OUR HIGHLY SPECIALIZED CAPABILITIES ENABLE US TO EFFICIENTLY MANAGE COMPLEX PROJECTS FOR:

- Drug types including small molecules, peptides, nucleic acids, highly potent APIs, controlled substances and BSL-2 microbials
- Specialized oral modified drug release including controlled, sustained, delayed, and pulsatile release
- Bioavailability enhancement of small molecules, oral biologics and microbials
- Regulatory and lifecycle management strategies including expedited approval pathways such as 5o5(b)(2)




## CUSTOM PRODUCTS TO MATCH YOUR SPECIFIC NEEDS

#### A range of size, color and other tailored options

In addition to our series of standard EUDRACAP® products, our EUDRACAP® Select platform provides you with flexible custom options including:

- Size: A range of sizes can be supplied
- · Color: Transparent, two-tone, full white or full colored
- Release profile: Many EUDRAGIT®, drug delivery and process technology options are available to match your specific immediate, delayed, sustained or modulated release profile or solubility enhancement requirements



## SOLVE YOUR SOLUBILITY ENHANCEMENT CHALLENGES

Our solubility enhancement service for particleengineered free-flowing amorphous solid dispersions

- Solubilizes highly challenging compounds
- Creates free-flowing powder through lean process with advanced particle-engineering control
- Leverages full therapeutic potential

Transform poorly soluble drugs into freeflowing amorphous solid dispersions

**EUDRATEC®** SoluFlow



## FAST, FLEXIBLE AND RELIABLE CLINICAL AND COMMERCIAL DRUG SUPPLY

- Sites
  - Germany and the USA
  - GMP system complies with EU guidelines and FDA guidelines
- HPAPI capabilities
  - OEB 3a/3b (OEL 1  $\mu$ g/cm³ 10  $\mu$ g/cm³)
- OEB 4: select cases
   (OEL 0.1 μg/cm³ 1 μg/cm³)
- Controlled substances
- Solvent capabilities

	PARTN	
Capability	GMP Scale	
Fluid bed coating	0.005 – 400 kg	
Automatic capsule filling	10,000 – 100,000 capsules/hour	
High-shear granulation	10 – 100 L	
Drug layering	0.004 – 400 kg	
Tablet compression	< 150,000 tablets/hour	
Tablet and capsule coating (drum coater)	0.8 – 125 L	
Direct pelletization (fluid bed technology)	0.004 – 100 kg	

5 Regulatory Support

# WORLDWIDE MONOGRAPH ACCEPTANCE. LOCAL MARKET EXPERTISE.















### PHARMACOPOEIAL MONOGRAPHS AND DMFS

- Global acceptance of monographs for EUDRAGIT® series across key regions including U.S., EU, Japan and China
- EUDRAGIT® types detailed in Type IV U.S.
   DMFs
- EXCiPACT™ certificate system for audit efficiency

### EXTENSIVE DOCUMENTATION SUPPORT

- Global quality systems (IPEC-GMP)
- Robust documentation to support NDAs and marketing authorizations including
  - Safety and toxicology packages
  - Polymer specifications
  - Letters of Authorization for DMFs
  - Detailed statements for special purposes

.......

202210

This information and all further technical advice are based on our present knowledge and experience. However, it implies no liability or other legal responsibility on our part, including with regard to existing third party intellectual property rights, especially patent rights. In particular, no warranty, whether express or implied, or guarantee of product properties in the legal sense is intended or implied. We reserve the right to make any changes according to technological progress or further developments. The customer is not released from the obligation to conduct careful inspection and testing of incoming goods. Performance of the product described herein should be verified by testing, which should be carried out only by qualified experts in the sole responsibility of a customer. Reference to trade names used by other companies is neither a recommendation, nor does it imply that similar products could not be used.

EUDRAGIT®, EUDRATEC® and EUDRACAP® are registered trademarks of Evonik Industries AG and its subsidiaries.

PHLORAL® is a proprietary technology from Intract Pharma Ltd.



#### **EVONIK OPERATIONS GMBH**

Health Care Business Line

healthcare@evonik.com www.evonik.com/healthcare